Generic Name and Formulations:
Guselkumab 100mg/mL; soln for SC inj; preservative-free.
Janssen Biotech, Inc.
Indications for TREMFYA:
Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
≥18yrs: 100mg by SC inj at Weeks 0 and 4, then every 8 weeks thereafter.
<18yrs: not established.
Use under physician supervision. May increase risk of infections. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolves. Evaluate for tuberculosis (TB) infection and treat latent TB prior to initiating. Monitor for signs/symptoms of active TB during and after therapy. Patients with active TB infection: do not initiate. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Consider completion of all age appropriate immunizations according to current guidelines before starting therapy. Pregnancy. Nursing mothers.
Concomitant live vaccines: not recommended. Concomitant CYP450 substrates with narrow therapeutic index: monitor and adjust dose as needed.
Upper respiratory infections, headache, inj site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, herpes simplex infections.
Single-dose prefilled syringe—1
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes